NASDAQ:VXRT Vaxart - VXRT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.08 -0.02 (-1.82%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.07▼$1.1350-Day Range$0.75▼$1.3052-Week Range$0.73▼$5.43Volume1.93 million shsAverage Volume1.76 million shsMarket Capitalization$141.75 millionP/E RatioN/ADividend YieldN/APrice Target$4.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Vaxart MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside339.8% Upside$4.75 Price TargetShort InterestBearish16.94% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$15,200 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.84) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.86 out of 5 starsMedical Sector697th out of 1,028 stocksBiological Products, Except Diagnostic Industry112th out of 168 stocks 3.3 Analyst's Opinion Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.75, Vaxart has a forecasted upside of 339.8% from its current price of $1.08.Amount of Analyst CoverageVaxart has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.94% of the outstanding shares of Vaxart have been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Vaxart has recently decreased by 2.28%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VXRT. Previous Next 1.9 News and Social Media Coverage News SentimentVaxart has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.Search Interest41 people have searched for VXRT on MarketBeat in the last 30 days. This is an increase of 156% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,200.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.80% of the stock of Vaxart is held by insiders.Percentage Held by InstitutionsOnly 38.66% of the stock of Vaxart is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vaxart are expected to decrease in the coming year, from ($0.84) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vaxart (NASDAQ:VXRT) StockVaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.Read More Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Email Address VXRT Stock News HeadlinesDecember 19, 2022 | finance.yahoo.comVaxart Names Phillip Lee as Chief Financial OfficerDecember 1, 2022 | finance.yahoo.comVaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding MothersFebruary 4, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 1, 2022 | finance.yahoo.comVaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding MothersNovember 22, 2022 | finance.yahoo.comVaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29November 11, 2022 | finance.yahoo.comVaxart Third Quarter 2022 Earnings: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021)November 8, 2022 | finance.yahoo.comVaxart Provides Business Update and Reports Third Quarter 2022 Financial ResultsNovember 8, 2022 | finance.yahoo.comVAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue EstimatesFebruary 4, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 1, 2022 | finance.yahoo.comVAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?October 20, 2022 | globenewswire.comVaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8 - GlobeNewswireOctober 20, 2022 | finance.yahoo.comVaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8October 10, 2022 | globenewswire.comVaxart to Present at World Vaccine Congress Europe 2022 on October 13 - GlobeNewswireOctober 10, 2022 | finance.yahoo.comVaxart to Present at World Vaccine Congress Europe 2022 on October 13October 4, 2022 | nasdaq.com2 Struggling Stocks to Avoid Right Now - NasdaqOctober 4, 2022 | fool.com2 Struggling Stocks to Avoid Right Now - The Motley FoolSeptember 19, 2022 | benzinga.comWhy Vaxart Shares Are Falling - Vaxart (NASDAQ:VXRT) - BenzingaSeptember 9, 2022 | seekingalpha.comVaxart Stock: Market Still Isn't Buying Oral Vaccine Thesis (NASDAQ:VXRT) - Seeking AlphaSeptember 7, 2022 | finance.yahoo.comVaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Yahoo FinanceSeptember 7, 2022 | benzinga.com(VXRT) – Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference - BenzingaSeptember 7, 2022 | finance.yahoo.comVaxart to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 3, 2022 | seekingalpha.comVaxart stock rises as COVID pill vaccine shows response, safety in trial - Seeking AlphaSeptember 2, 2022 | finance.yahoo.comVaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer - Yahoo FinanceSeptember 1, 2022 | investorplace.comWhat Is Going on With Vaxart (VXRT) Stock Today?September 1, 2022 | investorplace.comWhat Is Going on With Vaxart (VXRT) Stock Today? - InvestorPlaceSeptember 1, 2022 | globenewswire.comVaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate - GlobeNewswireSeptember 1, 2022 | finance.yahoo.comVaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine CandidateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Email Address VXRT Company Calendar Last Earnings11/08/2022Today2/04/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CUSIPN/A CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees110Year Founded2004Price Target and Rating Average Stock Price Forecast$4.75 High Stock Price Forecast$8.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+339.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,470,000.00 Net MarginsN/A Pretax Margin-65,745.28% Return on Equity-67.56% Return on Assets-53.76% Debt Debt-to-Equity RatioN/A Current Ratio5.54 Quick Ratio5.54 Sales & Book Value Annual Sales$890,000.00 Price / Sales159.27 Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book0.72Miscellaneous Outstanding Shares131,250,000Free Float127,574,000Market Cap$141.75 million OptionableNot Optionable Beta0.80 Social Links Key ExecutivesAndrei FloroiuPresident, Chief Executive Officer & DirectorPhillip Eric LeeChief Financial OfficerSean N. TuckerChief Scientific Officer & Senior Vice PresidentJames F. CummingsChief Medical OfficerRaymond D. StapletonChief Technology OfficerKey CompetitorsFusion PharmaceuticalsNASDAQ:FUSNCellectisNASDAQ:CLLSBioAtlaNASDAQ:BCABIkena OncologyNASDAQ:IKNATenaya TherapeuticsNASDAQ:TNYAView All CompetitorsInsiders & InstitutionsSG Americas Securities LLCSold 11,994 shares on 2/2/2023Ownership: 0.037%Simplex Trading LLCSold 22,100 shares on 2/2/2023Ownership: 0.000%Private Portfolio Partners LLCSold 25,380 shares on 2/1/2023Ownership: 0.090%W. Mark WatsonBought 20,000 shares on 12/28/2022Total: $15,200.00 ($0.76/share)Bank of New York Mellon CorpBought 42,535 shares on 12/8/2022Ownership: 0.355%View All Insider TransactionsView All Institutional Transactions VXRT Stock - Frequently Asked Questions Should I buy or sell Vaxart stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VXRT shares. View VXRT analyst ratings or view top-rated stocks. What is Vaxart's stock price forecast for 2023? 3 Wall Street research analysts have issued twelve-month price targets for Vaxart's stock. Their VXRT share price forecasts range from $1.50 to $8.00. On average, they expect the company's stock price to reach $4.75 in the next year. This suggests a possible upside of 339.8% from the stock's current price. View analysts price targets for VXRT or view top-rated stocks among Wall Street analysts. How have VXRT shares performed in 2023? Vaxart's stock was trading at $0.9609 at the beginning of 2023. Since then, VXRT stock has increased by 12.4% and is now trading at $1.08. View the best growth stocks for 2023 here. When is Vaxart's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our VXRT earnings forecast. How were Vaxart's earnings last quarter? Vaxart, Inc. (NASDAQ:VXRT) posted its earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.01. When did Vaxart's stock split? Vaxart's stock reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), Organigram (OGI) and Novan (NOVN). What is Vaxart's stock symbol? Vaxart trades on the NASDAQ under the ticker symbol "VXRT." Who are Vaxart's major shareholders? Vaxart's stock is owned by many different institutional and retail investors. Top institutional investors include Private Portfolio Partners LLC (0.09%), SG Americas Securities LLC (0.04%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital, Llc, Fuad Ahmad, Margaret Echerd, Robert A Yedid, Sean Tucker, Todd C Davis, W Mark Watson and Wouter Latour. View institutional ownership trends. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vaxart's stock price today? One share of VXRT stock can currently be purchased for approximately $1.08. How much money does Vaxart make? Vaxart (NASDAQ:VXRT) has a market capitalization of $141.75 million and generates $890,000.00 in revenue each year. The biotechnology company earns $-70,470,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. How many employees does Vaxart have? The company employs 110 workers across the globe. How can I contact Vaxart? Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The official website for the company is www.vaxart.com. The biotechnology company can be reached via phone at (650) 550-3500, via email at ir@vaxart.com, or via fax at 650-871-8580. This page (NASDAQ:VXRT) was last updated on 2/4/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.